Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

Caitlin E. Cox

October 27, 2023

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

L.A. McKeown

May 19, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Todd Neale

March 31, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Industry News

SMT Announces CE* Mark for the Most Deliverable Stent Supraflex Cruz

July 11, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2019

Caitlin E. Cox

May 31, 2019

News Conference News EuroPCR 2019

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

Caitlin E. Cox

May 21, 2019

Presentation EuroPCR 2019

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

Presenter: Clemens von Birgelen

May 21, 2019

News Industry News

BIOTRONIK Launches PK Papyrus Covered Coronary Stent in the US

April 10, 2019

News Daily News

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Michael O'Riordan

February 22, 2019

Advertisement

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

SMT Announces CE* Mark for the Most Deliverable Stent Supraflex Cruz

TCTMD’s Top 10 Most Popular Stories for May 2019

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

BIOTRONIK Launches PK Papyrus Covered Coronary Stent in the US

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content